JP2023515675A5 - - Google Patents

Info

Publication number
JP2023515675A5
JP2023515675A5 JP2022552573A JP2022552573A JP2023515675A5 JP 2023515675 A5 JP2023515675 A5 JP 2023515675A5 JP 2022552573 A JP2022552573 A JP 2022552573A JP 2022552573 A JP2022552573 A JP 2022552573A JP 2023515675 A5 JP2023515675 A5 JP 2023515675A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
kit
use according
administered
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022552573A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515675A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/020858 external-priority patent/WO2021178657A1/en
Publication of JP2023515675A publication Critical patent/JP2023515675A/ja
Publication of JP2023515675A5 publication Critical patent/JP2023515675A5/ja
Priority to JP2026037122A priority Critical patent/JP2026097988A/ja
Pending legal-status Critical Current

Links

JP2022552573A 2020-03-05 2021-03-04 Pd-1アンタゴニスト、ctla4アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法 Pending JP2023515675A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026037122A JP2026097988A (ja) 2020-03-05 2026-03-09 Pd-1アンタゴニスト、ctla4アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062985500P 2020-03-05 2020-03-05
US62/985,500 2020-03-05
PCT/US2021/020858 WO2021178657A1 (en) 2020-03-05 2021-03-04 Methods for treating cancer using a combination of a pd-1 antagonist, a ctla4 antagonist, and lenvatinib or a pharmaceutically acceptable salt thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026037122A Division JP2026097988A (ja) 2020-03-05 2026-03-09 Pd-1アンタゴニスト、ctla4アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法

Publications (2)

Publication Number Publication Date
JP2023515675A JP2023515675A (ja) 2023-04-13
JP2023515675A5 true JP2023515675A5 (cg-RX-API-DMAC7.html) 2024-03-11

Family

ID=77614229

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022552573A Pending JP2023515675A (ja) 2020-03-05 2021-03-04 Pd-1アンタゴニスト、ctla4アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法
JP2026037122A Pending JP2026097988A (ja) 2020-03-05 2026-03-09 Pd-1アンタゴニスト、ctla4アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026037122A Pending JP2026097988A (ja) 2020-03-05 2026-03-09 Pd-1アンタゴニスト、ctla4アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法

Country Status (6)

Country Link
US (1) US20230118596A1 (cg-RX-API-DMAC7.html)
EP (1) EP4114464A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023515675A (cg-RX-API-DMAC7.html)
KR (1) KR20220149740A (cg-RX-API-DMAC7.html)
CN (1) CN115443152A (cg-RX-API-DMAC7.html)
WO (1) WO2021178657A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023003032A (es) * 2020-09-15 2023-06-01 Merck Sharp & Dohme Llc Terapia de combinacion de un antagonista de pd-1 y un antagonista de lag3 y lenvatinib o una sal farmaceuticamente aceptable del mismo para el tratamiento de pacientes con cancer.
WO2023160517A1 (zh) * 2022-02-22 2023-08-31 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
US20250376525A1 (en) * 2022-06-28 2025-12-11 Qilu Pharmaceutical Co., Ltd. Pharmaceutical composition comprising mixed antibody of anti-ctla4 and anti-pd1 and therapeutic use thereof
EP4722358A1 (en) * 2023-06-02 2026-04-08 Ajou University Industry-Academic Cooperation Foundation Glycerol dehydratase variant and use thereof
WO2025002264A1 (zh) * 2023-06-30 2025-01-02 默沙东有限责任公司 包含偶联物的药物组合的治疗方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201690912A1 (ru) * 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
CN105296433B (zh) * 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
KR20240064733A (ko) * 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
HRP20201334T1 (hr) * 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
CN110505882A (zh) * 2017-03-31 2019-11-26 默沙东公司 用pd-1的拮抗剂和抗ctla4抗体的组合治疗癌症的组合物和方法
CA3060695A1 (en) * 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
CN119792515A (zh) * 2018-02-13 2025-04-11 默沙东有限责任公司 用抗pd-1抗体和抗ctla-4抗体治疗癌症的方法
WO2019222075A1 (en) * 2018-05-14 2019-11-21 Merck Sharp And Dohme Corp. Biomarkers for a combination therapy comprising lenvatinib and a pd-1 antagonist
EP4008730A4 (en) * 2019-08-02 2023-09-06 Akeso Pharmaceuticals, Inc. BISPECIFIC ANTI-CTLA4-ANTI-PD-1 ANTIBODY AND ITS USES

Similar Documents

Publication Publication Date Title
TWI780083B (zh) 抗pd-1抗體及組成物
JP2023510199A5 (cg-RX-API-DMAC7.html)
JP2018070648A5 (cg-RX-API-DMAC7.html)
AU2019210648A1 (en) Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
CN114286828A (zh) 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法
JP2019535254A5 (ja) 抗pd−l1抗体および変異型
JP2021513540A5 (cg-RX-API-DMAC7.html)
JP2014511179A5 (cg-RX-API-DMAC7.html)
JP2015534579A5 (cg-RX-API-DMAC7.html)
US11939381B2 (en) Bispecific antibodies targeting immune checkpoints
TW201902514A (zh) Pd-1抗體與vegf配體或vegf受體抑制劑聯合在製備治療腫瘤的藥物中的用途
RU2011103125A (ru) КОМБИНАЦИЯ АНТАГОНИСТА c-Met И АМИНОГЕТЕРОАРИЛА ДЛЯ ЛЕЧЕНИЯ РАКА
JP2022512851A5 (cg-RX-API-DMAC7.html)
JP2022543062A5 (cg-RX-API-DMAC7.html)
KR20160111001A (ko) 암에 대한 조합 요법
JP2023522630A (ja) 抗flt3抗体及び組成物
CN119173277A (zh) 包含sting激动剂的抗体药物缀合物、组合及使用方法
CN114450025A (zh) 使用包含多重酪氨酸激酶抑制剂和免疫检查点抑制剂的组合治疗癌症
EP3145544A1 (en) Ang2 antibodies
JP2021518348A5 (cg-RX-API-DMAC7.html)
EP4255472A2 (en) Combination therapy
CN120437318A (zh) 抗体药物偶联物和免疫检查点抑制剂的联合应用
JP2023543978A5 (cg-RX-API-DMAC7.html)
JP2023500480A5 (cg-RX-API-DMAC7.html)
JP2020507569A5 (cg-RX-API-DMAC7.html)